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Abstract Electroencephalographic (EEG) biofeedback
has been employed in substance use disorder (SUD) over
the last three decades. The SUD is a complex series of
disorders with frequent comorbidities and EEG abnormal-
ities of several types. EEG biofeedback has been employed
in conjunction with other therapies and may be useful in
enhancing certain outcomes of therapy. Based on published
clinical studies and employing efﬁcacy criteria adapted by
the Association for Applied Psychophysiology and Bio-
feedback and the International Society for Neurofeedback
and Research, alpha theta training—either alone for alco-
holism or in combination with beta training for stimulant
and mixed substance abuse and combined with residential
treatment programs, is probably efﬁcacious. Considerations
of further research design taking these factors into account
are discussed and descriptions of contemporary research
are given.
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Introduction
Substance use disorders (SUD) include disorders related to
the taking of a drug of abuse (including alcohol), and
represent the most common psychiatric conditions (APA
2000) resulting in serious impairments in cognition and
behavior. Acute and chronic drug abuse results in signiﬁ-
cant alteration of the brain activity detectable with
quantitative electroencephalography (qEEG) methods. The
treatment of addictive disorders by electroencephalo-
graphic (EEG) biofeedback (or neurofeedback, as it is often
called) was ﬁrst popularized by the work of Eugene Pen-
iston (Peniston and Kulkosky 1989, 1990, 1991) and
became popularly known as the Peniston Protocol. This
approach employed independent auditory feedback of two
slow brain wave frequencies, alpha (8–13 Hz) and theta
(4–8 Hz) in an eyes closed condition to produce a hypna-
gogic state. The patient was taught prior to neurofeedback
to use what amounts to success imagery (beingsober,
refusing offers of alcohol, living conﬁdently, and happy) as
they drifted down into an alpha-theta state. Repeated ses-
sions reportedly resulted in long-term abstinence and
changes in personality testing. Because the method seemed
to work well for alcoholics, it has been tried in subjects
with cannabis dependence and stimulant dependence—but
with limited success until the work of Scott and Kaiser
(Scott and Kaiser 1998; Scott et al. 2002, 2005). They
described treating stimulant abusing subjects with atten-
tion-deﬁcit type EEG biofeedback protocols, followed by
the Peniston Protocol, with substantial improvement in
program retention and long-term abstinence rates. This
approach has become known widely as the Scott–Kaiser
modiﬁcation (of the Peniston Protocol).
This ‘‘white paper’’ on EEG biofeedback for SUD
will offer an assessment of efﬁcacy according to the
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Applied Psychophysiology and Biofeedback (AAPB) and
the International Society for Neurofeedback and Research
(ISNR). Assessing the efﬁcacy of neurofeedback for SUD
involves several considerations. The ﬁrst of these involves
difﬁculties assessing the efﬁcacy of any treatment method
for SUD. Outcome benchmarks (i.e., total abstinence,
improved function and quality of life) and time points of
outcome (i.e., one year, two years post treatment) are not
clearly established.
Outcome assessment for treatment of SUD in itself is a
complex topic well beyond the scope of this article.
Because different drugs of abuse are associated with dif-
ferent patterns of EEG abnormality, as will be discussed in
detail in this article, it is difﬁcult to assign broad-brush
EEG biofeedback solutions to SUD as a whole. Any
statements of efﬁcacy will need to describe speciﬁc EEG
biofeedback protocols for speciﬁc substances of abuse.
Furthermore substance abuse is often mixed substance type
and comorbid conditions are common and vary from sub-
ject to subject, as will also be borne out in this article. As of
yet there are no gold standard medication or other treat-
ments for the various types of SUD and efﬁcacy of any
SUD treatment method likely falls into the ‘‘possibly
effective’’ to ‘‘probably effective’’ range according to the
efﬁcacy guidelines jointly established by the AAPB and
ISNR. Finally, all of the studies of EEG biofeedback in
SUD to date employ EEG biofeedback as an add on to
cognitive behavioral or twelve step treatment regimes, so
any statements of efﬁcacy would have to acknowledge that
EEG biofeedback is not a stand alone treatment for SUD.
This article is divided into several sections. In the ﬁrst
section after ‘‘Introduction,’’ we review SUD prevalence
and describe qEEG changes typical for the most wide-
spread drugs of abuse (alcohol, marijuana, heroin, cocaine,
and methamphetamine). The second section describes
treatment studies employing EEG biofeedback in SUD.
Studies that have used the Peniston Protocol are described
ﬁrst, along with critical commentaries of these studies. In
the second part of this section, a description of the Scott–
Kaiser modiﬁcation is given, along with some discussion of
a rationale for why this approach may be more successful
with stimulant abusers. This section also describes some
current research. The third section assesses efﬁcacy of the
Peniston Protocol and the Scott–Kaiser modiﬁcation. The
fourth section takes a look at the clinical implications of
comorbidities in neurobiofeedback treatment of alcohol
and drug abuse. The ﬁfth section discusses the clinical
implications of standard cognitive-behavioral therapies in
SUD treatment and reviews the rationale for the application
of qEEG-guided neurofeedback intervention in SUD in
conjunction with these therapies. The ﬁnal section sum-
marizes ﬁndings in qEEG and neurofeedback in SUD and
additionally proposes further directions for clinical
research in this area.
This article represents an update of earlier reviews
(Trudeau 2000, 2005a, b) of EEG biofeedback for addic-
tive disorders extended with a review on qEEG in SUD.
This review is presented as one of a series of papers in both
The Journal of Neurotherapy and The Journal of Applied
Psychophysiology & Biofeedback describing and reviewing
biofeedback applications for adult populations. No attempt
will be made to review the ﬁelds of qEEG and neurobio-
feedback generally (see current reviews by Hammond
2006; Kaiser 2006), or the ﬁeld of addictive disorders
generally, although some references will be made to spe-
ciﬁcs the authors feel are pertinent to a discussion of
emerging concepts of qEEG as a sensitive tool for the brain
function assessment in SUD, and EEG biofeedback as a
treatment approach for SUD.
SUD Prevalence and qEEG Changes
Drug addiction can be described as a mental disorder with
idiosyncratic behavioral, cognitive, and psychosocial fea-
tures. The SUD commonly referred to as ‘‘drug addiction’’
is characterized by physiological dependence accompanied
by the withdrawal syndrome on discontinuance of the drug
use, psychological dependence with craving, the patho-
logical motivational state that leads to the active drug-
seeking behavior, and tolerance, expressed in the escalation
of the dose needed to achieve a desired euphoric state.
Drug addiction is a chronic, relapsing mental disease that
results from the prolonged effects of drugs on the brain
(Dackis and O’Brain 2001; Volkow et al. 2003, 2004).
Drug addiction can take control of the brain and behavior
by activating and reinforcing behavioral patterns that are
excessively directed to compulsive drug use (Di Chiara
1999; Gerdeman et al. 2003).
From the 11 classes of substances listed in the DSM-IV
we will discuss in our review only alcohol, cannabis
(marijuana), heroin, and such psychostimulants as cocaine
and methamphetamine. Addiction leads to behavioral,
cognitive, and social adverse outcomes that incur sub-
stantial costs to society. In 2002, it was estimated from the
Substance Abuse and Mental Health Service Administra-
tion (SAMHSA 2004) that 22 million Americans have a
substance abuse or dependence disorder, and 2 million of
them were current cocaine users (Vocci and Ling 2005). In
2005, there were 2.4 million persons who were current
cocaine users, which is more than in 2004 (SAMHSA
2006). The number of current crack users increased from
467,000 in 2004 to 682,000 in 2005. According to the 2004
revised National Survey on Drug Use and Health, nearly
12 million Americans have tried methamphetamine, and
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123583,000 of them are chronic methamphetamine users
(SAMHSA 2004). In 2005, an estimated 22.2 million
persons aged 12 or older were classiﬁed with substance
dependence or abuse in the past year (9.1% of the popu-
lation aged 12 or older). Of these, 3.3 million were
classiﬁed with dependence on or abuse of both alcohol and
illicit drugs, 3.6 million were dependent on or abused illicit
drugs but not alcohol, and 15.4 million were dependent on
or abused alcohol but not illicit drugs. There were
18.7 million persons classiﬁed with dependence on or
abuse of alcohol in 2005 (7.7%). The speciﬁc illicit drugs
that had the highest levels of past year dependence or abuse
in 2005 were marijuana, followed by cocaine and pain
relievers. Of the 6.8 million persons aged 12 or older
classiﬁed with dependence on or abuse of illicit drugs,
4.1 million were dependent on or abused marijuana in
2005. This number represents 1.7% of the total population
aged 12 or older and 59.9% of all those classiﬁed with
illicit drug dependence or abuse. Marijuana was the most
commonly used illicit drug (14.6 million past month
users). In 2005, it was used by 74.2% of current illicit drug
users. Among current illicit drug users, 54.5% used only
marijuana, 19.6% used marijuana and another illicit drug,
and the remaining 25.8% used only an illicit drug other
than marijuana in the past month (SAMHSA 2006).
Fatal poisoning, which include overdoses (ODs) on
illicit drugs, alcohol, and medications, is the leading cause
of injury death for individuals age 35–44 and the third
leading cause of injury death overall, trailing motor vehicle
accidents and ﬁrearm-related deaths (CDC 2004). Heroin-
related ODs have increased at an alarming rate in portions
of the US and other countries (Darke and Hall 2003;
Landen et al. 2003), and OD has surpassed HIV infection
as the primary cause of death for heroin users. Not sur-
prisingly, heroin is frequently associated with opioid-
related ODs, both as a single drug and in combination with
other substances (CDC 2004).
Many patients seeking treatment for addiction have
multiple drug dependencies and psychiatric comorbidities
(Volkow and Li 2005). Information from epidemiological
surveys indicates that drug addiction is a common phe-
nomenon and is associated with signiﬁcant effects on both
morbidity and mortality. Large individual and societal
costs of drug abuse make research and treatment of drug
addiction imperative (French et al. 2000; Mark et al.
2001). Recently through intensive clinical neurophysio-
logical research and biological psychiatric studies many
speciﬁc components of cognitive, emotional, and behav-
ioral deﬁcits typical for SUD have been identiﬁed and
investigated. However, the practical values of these cog-
nitive neuroscience and applied psychophysiology-based
treatment (e.g., neurofeedback) ﬁndings depend on a fur-
ther integration of these methodological approaches.
qEEG in Substance Use Disorders
EEG in Alcoholism
EEG alterations have been described extensively in alco-
holic patients (Porjesz and Begleiter 1998), but any attempt
at drawing a common picture from qEEG data is difﬁcult
due to signiﬁcant methodological differences, such as dif-
ferent deﬁnitions of frequency bands, different ﬁltering
methodology, number of channels, reference choice, etc.
However, most reports of alcoholic patients agree in
describing alterations mainly within the beta (Bauer 1997,
2001a; Costa and Bauer 1997; Rangaswamy et al. 2002,
2004) and/or alpha bands (Finn and Justus 1999).
The qEEG and LORETA mapping studies of detoxiﬁed
alcohol-dependent patients, as compared with normal
controls, showed an increase in absolute and relative beta
power and a decrease in alpha and delta/theta power
(Saletu et al. 2002), which is in agreement with earlier
reports of low-voltage fast EEG patterns, as often
encountered by visual EEG inspection (Niedermeyer and
Lopes da Silva 1982). As slow activities are considered to
be inhibitory, alpha activity may be viewed as an expres-
sion of normal brain functioning and fast beta activities as
excitatory, the low-voltage fast desynchronized patterns
may be interpreted as hyperarousal of the central nervous
system (CNS) (Saletu-Zyhlarz et al. 2004). The investiga-
tions by Bauer (2001a) and Winterer et al. (1998) showed a
worse prognosis for the patient group with a more pro-
nounced frontal CNS hyperarousal. It may be hypothesized
that these hyperaroused relapsing patients require more
CNS sedation than abstaining ones.
The EEG maps of alcohol-dependent patients differ
signiﬁcantly from those of normal controls and patients
suffering from other mental disorders and might be useful
for diagnostic purposes (Pollock et al. 1992; Saletu et al.
2002; Saletu-Zyhlarz et al. 2004). Decreased power in slow
bands in alcoholic patients may be an indicator of brain
atrophy and chronic brain damage, while an increase in the
beta band may be related to various factors such as medi-
cation use, family history of alcoholism, and/or
hallucinations, suggesting a state of cortical hyperexcit-
ability (Coutin-Churchman et al. 2006).
Abnormalities in resting EEG are often associated with a
predisposition to development of alcoholism. Subjects with
a family history of alcoholism were found to have reduced
relative and absolute alpha power in occipital and frontal
regions and increased relative beta in both regions com-
pared with subjects with a negative family history of
alcoholism. These results suggest that resting EEG alpha
abnormalities are associated with risk for alcoholism,
although their etiological signiﬁcance is unclear (Finn and
Justus 1999).
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chronization of brain activity than light drinkers as
reﬂected by differences in resting EEG coherence
(Kaplan et al. 1985, 1988; Michael et al. 1993; Winterer
et al. 2003a) and power (e.g., Bauer 2001a b; Enoch
et al. 2002; Rangaswamy et al. 2002; Saletu-Zyhlarz et
al. 2004). Most differences in EEG coherence and power
are found in the alpha and beta bands. Non-alcohol-
dependent relatives of alcohol-dependent individuals also
have EEG differences in alpha and beta coherence
(Michael et al. 1993) and power (Bauer and Hesselbrock
2002; Finn and Justus 1999; Rangaswamy et al. 2002,
2004) as compared to subjects without alcohol-dependent
relatives. This indicates that differences in functional
brain activity as measured with qEEG in alcohol-
dependent patients not only relate to the impact of long-
term alcohol intake, but possibly also to genetic factors
related to alcohol dependence.
Both alcohol dependence (Schuckit and Smith 1996)
and EEG patterns (Van Beijsterveldt and Van Baal 2002)
are highly heritable. In addition, some genes coding for
GABA receptors in the brain, which mediate the effects of
alcohol, are related to certain EEG patterns (Porjesz et al.
2005; Winterer et al. 2003b). Moreover, some GABA-
receptor genes that are related to EEG patterns are also
associated with the risk to develop alcohol dependence.
These associations again suggest that genetic factors play a
major role in the EEG differences associated with alcohol
dependence.
The EEG coherence analysis is a technique that inves-
tigates the pairwise correlations of power spectra obtained
from different electrodes. It measures the functional
interaction between cortical areas in different frequency
bands. A high level of coherence between two EEG signals
indicates a co-activation of neuronal populations and pro-
vides information on functional coupling between these
areas (Franken et al. 2004). De Bruin et al. (2004, 2006)
investigated the pure effects of alcohol intake on syn-
chronization of brain activity, while minimizing the
confounding inﬂuence of genetic factors related to alcohol
dependence. They showed that heavily drinking students
with a negative family history had stronger EEG syn-
chronization at theta and gamma frequencies than lightly
drinking students with a negative family history. This study
suggests that, in students, heavy alcohol intake has an
impact on functional brain activity, even in the absence of
genetic factors related to alcohol dependence.
The ﬁndings of studies on the effects of alcohol
dependence on EEG coherence can be summarized as
follows: Kaplan et al. (1985) reported lower frontal alpha
and slow-beta coherence in alcohol-dependent males and
females. Michael et al. (1993) found higher central alpha
and slow-beta coherence, but lower parietal alpha and
slow-beta coherence in males with alcohol dependence.
Winterer et al. (2003a, b) described higher left-temporal
alpha and slow-beta coherence and higher slow-beta
coherence at right-temporal and frontal electrode pairs in
alcohol-dependent males and females. De Bruin et al
(2006) showed that moderate-to-heavy alcohol consump-
tion is associated with differences in synchronization of
brain activity during rest and mental rehearsal. Heavy
drinkers displayed a loss of hemispheric asymmetry of
EEG synchronization in the alpha and slow-beta band.
Moderately and heavily drinking males additionally
showed lower fast-beta band synchronization.
Therefore, qEEG alterations have been described
extensively in alcoholics. Most EEG reports in alcoholic
patients agree in describing alterations mainly within the
beta and alpha bands. Patients with a more pronounced
frontal hyperarousal have worse prognosis. Decreased
power in slow bands in alcoholic patients may be an
indicator of chronic brain damage, while increase in beta
band may be related to various factors suggesting cortical
hyperexcitability. Abnormalities in resting EEG are highly
heritable traits and are often associated with a predisposi-
tion to alcoholism development. The studies on the effects
of alcohol dependence on EEG coherence can be summa-
rized as lower frontal alpha and slow-beta coherence in
alcohol-dependent patients with some topographical
coherence abnormality differences between alcohol-
dependent males and females.
EEG in Marijuana Abuse
Several lines of evidence suggest that cannabis (marijuana,
tetrahydrocannabinol—THC) may alter functionality of the
prefrontal cortex and thereby elicit impairments across
several domains of complex cognitive function (Egerton
et al. 2006). Several studies in both humans and animals
have shown that cannabinoid exposure results in alterations
in prefrontal cortical activity (Block et al. 2002; O’Leary
et al. 2002; Whitlow et al. 2002), providing evidence that
cannabinoid administration may affect the functionality of
this brain area. Despite the fact that a number of transient
physiological, perceptual and cognitive effects are known
to accompany acute chronic marijuana (THC) exposure in
humans, persistent qEEG effects in humans resulting from
continuing exposure to this drug have been difﬁcult to
demonstrate (Wert and Raulin 1986). In early reviews of
EEG and ERP studies of acute and chronic THC exposure
in humans (Struve et al. 1989, 1994), it was reported that
signiﬁcant associations between chronic exposure and
clinically abnormal EEG patterns had not been demon-
strated and that attempts to use visual EEG analyses to
detect transient acute THC exposure induced EEG
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effects across studies.
Quantitative methods of analyzing EEG spectra from
single posterior scalp derivations began to be applied to
studies of acute THC exposure. These early studies
reported that acute THC exposure produced transient
increases in either posterior alpha power, decreases in
mean alpha frequency or increases in alpha synchrony
(Fink et al. 1976; Struve et al. 1989; Tassinari et al. 1976;
Volavka et al. 1971, 1973). These studies found that THC
produced a transient dose-dependent rapid onset: (1)
increase in relative power (amount, abundance) of alpha;
(2) decrease in alpha frequency; and (3) decrease in relative
power of beta as measured from posterior scalp electrodes.
Later studies of Struve et al. (1998, 1999, 2003) dem-
onstrated and replicated a signiﬁcant association between
chronic marijuana use and topographic qEEG patterns of
persistent ‘‘alpha hyperfrontality’’ (i.e., elevations of alpha
absolute power, relative power, and interhemispheric
coherence over frontal cortex) as well as reductions of
alpha mean frequency. These ﬁndings from chronic users
are consistent with both non-topographic (Hockman et al.
1971; Tassinari et al. 1976; Volavka et al. 1973) and
topographic (Lukas et al. 1995; Struve et al. 1994) tran-
sient EEG effects of acute THC administration. Therefore,
chronic daily THC use was found to be associated with
distinct topographic qEEG features. Compared with non-
users, THC users had signiﬁcant elevations of absolute and
relative power, and interhemispheric coherence of alpha
activity over the bilateral frontal cortex (referred to as
‘‘alpha hyperfrontality’’). A second ﬁnding was that the
voltage (not relative power or coherence) of all non-alpha
frequency bands was signiﬁcantly elevated in THC users,
although the voltage increase was generalized and not
frontally dominant. A third ﬁnding involved a widespread
decrease in the relative power of delta and beta activity for
cannabis users, particularly over the frontal cortical
regions. A fourth ﬁnding was that interhemispheric
coherence of theta and possibly delta activity was also
signiﬁcantly elevated over frontal cortex for marijuana
users. Because most studies included daily THC users and
non-users drawn from an inpatient psychiatric population,
the effects of psychiatric diagnoses or medication were not
controlled.
Thus, qEEG studies on acute THC exposure reported a
transient dose-dependent increase in relative power of
alpha, decrease in alpha frequency, and decrease in relative
power of beta at posterior EEG recording sites. Chronic
marijuana abuse is known to result in a number of physi-
ological, perceptual and cognitive effects, but persistent
qEEG effects from continuing exposure to THC have been
difﬁcult to demonstrate. However, recent studies of Struve
and his colleagues have demonstrated a signiﬁcant
association between chronic marijuana use and topographic
qEEG patterns of persistent elevations of alpha absolute
power, relative power, and interhemispheric coherence
over frontal cortex, as well as reductions of alpha mean
frequency. Another important qEEG ﬁnding was the ele-
vated voltage of all non-alpha bands in THC users. A third
qEEG ﬁnding involved a widespread decrease in the rela-
tive power of delta and beta activity over the frontal
cortical regions in marijuana users.
EEG in Heroin Addiction
Only a few studies have investigated qEEG changes in
heroin addicts. Qualitative changes were observed in more
than 70% of heroin addicts in the early abstinence (acute
withdrawal) period, and these included low-voltage back-
ground activity with diminution of alpha rhythm, an
increase in beta activity, and a large amount of low-
amplitude delta and theta waves in central regions
(Olivennes et al. 1983; Polunina and Davydov 2004).
Franken et al. (2004) found that abstinent heroin-dependent
subjects have an enhanced fast beta power compared with
healthy controls, and this ﬁnding is concordant with other
EEG studies on alcohol and cocaine abusing subjects
(Costa and Bauer 1997; Herning et al. 1994b; Rangaswamy
et al. 2004; Roemer et al. 1995). Spectral power and event-
related potentials (ERP) in heroin addicts strongly relate to
abstinence length (Shufman et al. 1996, Bauer 2001a;
Polunina and Davydov 2004). Most studies showed
considerable or even complete normalization of EEG
spectral power or magnitude of ERP components in heroin
ex-addicts who maintained abstinence for at least 3 months
(Bauer 2001b, 2002; Costa and Bauer 1997; Papageorgiou
et al. 2001; Polunina and Davidov 2004; Shufman et al.
1996).
Some quantitative changes were also reported in meth-
adone-maintenance heroin addicts (Gritz et al. 1975),
current heroin addicts, and subjects in heroin abstinence
less than 80 days (Shufman et al. 1996). Gritz et al. (1975)
demonstrated a signiﬁcant slowing of occipital alpha
rhythm peak frequency in 10 methadone-maintained
patients and the same trend in 10 abstinent heroin-addicted
subjects. In one study (Polunina and Davydov 2004),
slowing of slow alpha (8–10 Hz) mean frequency was
signiﬁcantly related to the amount of heroin taken by these
patients daily before withdrawal. The prolongation of ERP
component latencies in heroin addicts was also reported
(Papageorgiou et al. 2001), and these delays signiﬁcantly
correlated with years of heroin use, rather than with
abstinence length in the study of Bauer (1997). Polunina
and Davydov (2004) demonstrated frequency shifts in the
fast alpha range at the frontal and central recording sites
Appl Psychophysiol Biofeedback (2008) 33:1–28 5
123and a slowing of slow alpha mean frequency at the central,
temporal, and occipital sites of recording in heroin abusers
who used heroin for at least 18 months.
In general, pronounced desynchronization is character-
istic for acute heroin withdrawal, but as it was mentioned
above, several studies (Bauer 2001a, 2002; Costa and
Bauer 1997; Papageorgiou et al. 2001; Polunina and
Davydov 2004; Shufman et al. 1996) showed that spectral
power of EEG tends to normalize almost completely after
several weeks of abstinence. The most consistent changes
in EEG of heroin addicts were reported in alpha and beta
frequencies, and included a deﬁcit in alpha activity and an
excess of fast beta activity in early heroin abstinence. The
latter abnormality appears to reverse considerably when
heroin intake is stopped for several months, and therefore it
may be viewed as an acute withdrawal effect. The
dynamics and characteristics of spectral power changes
within the early opiate withdrawal suggest the participation
of catecholamine imbalances, especially noradrenaline and
perhaps to a lesser degree dopamine, which are widely
recognized as a main cause of opiate physical dependency
symptoms (Devoto et al. 2002; Maldonado 1997). Acute
opiate administration has been shown to increase, while
abstinence from chronic opiate use has been shown to
decrease extracellular dopamine (DA) in the nucleus ac-
cumbens. In contrast, extracellular DA in the prefrontal
cortex is not modiﬁed by acute opiate use, but is markedly
increased during morphine and heroin abstinence syndrome
(Devoto et al. 2002). Relationships between theta and beta
frequencies shifts and neurotransmitter imbalances char-
acteristic for heroin withdrawal remain unclear.
Withdrawal state in heroin addicts is known to elicit a
strong craving for drug, anxiety, nervousness, deﬁcits in
inhibitory control, dysphoric motivational state, and intru-
sive thoughts related to drugs (Franken 2003; Franken
et al. 1999, 2004; Stormark et al. 2000). Research on
functional connectivity in drug withdrawal states is
restricted to a few studies on coherence of the EEG signal
in abstinent heroin users (Franken et al. 2004; Fingelkurts
et al. (2006a), active heroin abusers (Fingelkurts et al.
2006b), and in abstinent polysubstance abusers (Roemer
et al. 1995). In a study on 22 opioid-dependent patients
under acute opioid inﬂuence, Fingelkurts et al. (2006b)
showed that longitudinal opioid exposure impairs cortical
local and remote functional connectivity, and found that
local connectivity increased, whereas the remote one
decreased. These ﬁndings were interpreted as speciﬁc signs
of independent processing in the cortex of chronic heroin
addicts. It has been suggested that such independent pro-
cesses may constitute the candidate mechanism for a well-
documented pattern of impairment in addicts that expresses
the lack of integration of different cognitive functions for
effective problem solving and helps to explain the observed
deﬁcits in abstract concept formation, behavioral control,
and problems in the regulation of affect and behavior.
Speciﬁcally, Fingelkurts et al. (2006b) found that the
number and strength of remote functional connections
among different cortical areas estimated by the index of
EEG synchrony was signiﬁcantly higher in patients in
acute heroin withdrawal than in healthy controls for most
categories of functional connections. Although this result
was observed in the alpha as well as in the beta frequency
bands, it was most prominent for the beta range. In the
same patient sub-sample under acute opioid inﬂuence the
authors (Fingelkurts et al. 2006a) observed the opposite: a
signiﬁcant decrease in the number and strength of remote
functional connections, when compared with healthy con-
trols. Thus, the increase of remote synchronicity among
cortical areas during the short-term withdrawal period may
indicate the selective attentional focus on cues and mem-
ories related to drugs while ignoring neutral cues (Franken
et al. 2000; Sokhadze et al. 2007). Generally this can
explain a narrowing of the behavioral repertoire and
compulsive drug seeking in abstinent addicted subjects
(Vanderschuren and Everitt 2004). Therefore, the elevated
synchrony within the beta frequency band in these studies
(Fingelkurts et al. 2006a, b) may reﬂect a state of CNS
activation toward reward-seeking behavior, with this being
a prerequisite of relapse among opiate drug dependent
patients (Bauer 2001a).
qEEG changes in heroin addicts in the acute withdrawal
period have been described as low-voltage background
activity with a diminution of alpha rhythm, an increase in
beta activity, and a large amount of low-amplitude delta
and theta waves in central regions. In general, pronounced
desynchronization is characteristic for acute heroin with-
drawal, but the spectral power of EEG tends to normalize
almost completely after several weeks of abstinence. The
most consistent changes in EEG of heroin addicts were
reported in the alpha and beta frequencies, and included a
deﬁcit in alpha activity and an excess of fast beta activity in
early heroin abstinence. The excess of beta appears to
reverse considerably when heroin intake is stopped for
several months, and therefore it may be viewed as an acute
withdrawal effect. Recent studies found that the number
and strength of remote functional connections among dif-
ferent cortical areas estimated by the index of EEG
synchrony for the beta range was signiﬁcantly higher in
patients in acute heroin withdrawal than in healthy controls
for most categories of functional connections.
EEG in Cocaine Addiction
Qualitative and quantitative EEG measures are highly sen-
sitive to the acute and chronic effects of neurointoxication
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effects from withdrawal and long-term abstinence from
cocaine use (Ehlers et al. 1989). However, some EEG
characteristics observed in cocaine addicts are considered to
be due to the toxic effects of this drug on the brain, whereas
some EEG characteristics in cocaine addicts may also indi-
cate a predisposition toward the development of SUD
(Porjesz et al. 2005).
Hans Berger (1937, cited by Gloor 1969; Herning et al.
1985) was the ﬁrst to study the effects of cocaine on human
EEG, reporting an increase in activity in the beta band-
width. This was replicated in subsequent studies with a
larger number of subjects (Alper 1999; Alper et al. 1990,
1998; Costa and Bauer 1997; Herning et al. 1985; Noldy
et al. 1994; Prichep et al. 1996, 1999, 2002; Roemer et al.
1995). Beside beta effects, studies have reported an
increase in delta activity (Herning et al. 1985) and frontal
alpha activity (Herning et al. 1994b), while others have
reported an increase in alpha wave EEG associated with
bursts of cocaine-induced euphoria (Lukas 1991). More
recently, researchers have begun analyzing qEEG proﬁles
of cocaine-dependent patients using the spectral power of
each primary bandwidth over the different topographic
cortical areas. Excess alpha activity (Alper et al. 1990;
Herning et al. 1994b; Lukas 1991; Prichep et al. 1996) and
decreased delta activity (Alper et al. 1990; Noldy et al.
1994; Prichep et al. 1996; Roemer et al. 1995) have been
reported, while others have reported increased beta power
(Herning et al. 1985, 1994b; Noldy et al. 1994) in cocaine-
dependent patients, recorded in eyes closed, resting con-
ditions. The qEEG abnormalities, primarily found in
anterior cortical regions, were shown to correlate with the
amount of prior cocaine use (Herning et al. 1996a; Prichep
et al. 1996; Roemer et al. 1995; Venneman et al. 2006).
The qEEG has been used more often to characterize the
effects of withdrawal in cocaine-dependent patients. Sev-
eral studies reported that during protracted abstinence from
cocaine qEEG effects are featured by long-lasting increases
in alpha and beta bands together with reduced activity in
delta and theta bands (Alper et al. 1990; Prichep et al.
1996; Roemer et al. 1995).
Recently Reid et al. (2006) investigated qEEG proﬁles
in cocaine-dependent patients in response to an acute,
single-blind, self-administered dose of smoked cocaine
base (50 mg) versus placebo. Cocaine produced a rapid
increase in absolute theta, alpha, and beta power over the
prefrontal cortex, lasting up to 25 min after administration
of the drug. The increase in theta power was correlated
with a positive subjective drug effect (‘‘high’’), and the
increase in alpha power was correlated with nervousness.
Cocaine also produced a similar increase in delta coherence
over the prefrontal cortex, which was correlated with ner-
vousness. Placebo resulted only in a slight increase in alpha
power over the prefrontal cortex. These data demonstrate
the involvement of the prefrontal cortex in the qEEG
response to acute cocaine, and indicate that slow wave
qEEG, delta and theta activity are involved in the processes
related to experiencing rewarding properties of cocaine.
Prichep et al. (1999, 2002) extended the idea of relating
baseline EEG activity to outcome in cocaine-dependent
patients in treatment programs. Subjects with cocaine
dependence have persistent changes in brain function
assessed with qEEG methods, present when evaluated at
baseline, 5–14 days after last reported crack cocaine use,
and persistent at one and six month follow-up evaluations
(Alper 1999; Alper et al. 1990, 1998; Prichep et al. 1996,
2002; Venneman et al. 2006). Several recent studies
employing qEEG techniques have already demonstrated an
association between the amount of beta activity in the
spontaneous EEG and relapse in cocaine abuse (Bauer
1997, 2001a). A decrease in the delta and theta bands of the
EEG can be regarded as a speciﬁc sign of brain
dysfunction.
However, this sign, as well as other qEEG abnormal
patterns, can be found in many different psychiatric dis-
orders and none of them can be considered as
pathognomonic of any speciﬁc mental or neurological
disorder. EEG coherence in cocaine addiction was inves-
tigated in only one study (Roemer et al. 1995). The authors
reported globally reduced interhemispheric coherence in
the delta and theta bands, and frontally in the beta band. It
should be noted that subjects in this study were cocaine-
preferring polysubstance abusers during abstinence and
these results can hardly be generalized to crack cocaine-
only users or other categories of cocaine-dependent sub-
jects not enrolled in any treatment.
Therefore, acute effects of smoked crack cocaine have
been shown to produce a rapid increase in absolute theta,
alpha, and beta power over the prefrontal cortex, lasting up
to half-an-hour after administration of the drug. The
increase in theta power was reported to correlate with a
positive subjective drug effect, while the increase in alpha
power was reported to correlate with nervousness. qEEG
measures are also sensitive to the acute and chronic effects
of cocaine, as well as the effects from withdrawal and long-
term abstinence from cocaine use. Some EEG character-
istics observed in cocaine addicts are considered to be due
to the neurotoxic effects, whereas some EEG characteris-
tics in cocaine addicts may also indicate a predisposition
toward the development of cocaine addiction. qEEG has
been used more often to characterize the effects of with-
drawal in cocaine-dependent patients. During protracted
abstinence from cocaine qEEG effects are featured by
long-lasting increases in alpha and beta bands together with
reduced activity in delta and theta bands. Several recent
studies employing qEEG techniques have demonstrated an
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spontaneous EEG and relapse in cocaine abuse.
EEG in Methamphetamine Addiction
Several studies have examined the neurobiological conse-
quences of methamphetamine dependence using qEEG
methods (e.g., Newton et al. 2003, 2004). It was found that
methamphetamine dependent patients exhibited a signiﬁ-
cant power increase in the delta and theta bands as
compared to non-drug-using controls (Newton et al. 2003).
These results are in accordance with other neurocognitive
studies (Kalechstein et al. 2003) suggesting that metham-
phetamine abuse is associated with psychomotor slowing
and frontal executive deﬁcits. Within the methamphet-
amine-dependent subjects, increased theta qEEG power
was found to correlate with response time and was
accompanied with reduced accuracy (Newton et al. 2004).
To our knowledge, qEEG patterns associated with acute
withdrawal and recent abstinence in methamphetamine
dependence have not yet been sufﬁciently described. One
study reported (Newton et al. 2003) that methamphetamine
dependent volunteers with 4 days of abstinence had
increased EEG power in the delta and theta but not in the
alpha and beta bands. Within the methamphetamine
dependent group, a majority of the conventional EEGs
were abnormal (64%), compared to 18% in the non-
methamphetamine using group.
The qEEG may provide a sensitive neurophysiological
outcome measure of methamphetamine abuse-related per-
sistent alterations in neurocognitive functions (Newton
et al. 2004). In a study by Simon et al. (2002), when per-
formance of patients with SUD was compared to their
matched non-using control groups, both methamphetamine
and cocaine abusers were impaired on cognitive measures,
but the type and degree of impairments were somewhat
different. Some of these differences between metham-
phetamine and cocaine effects on cognitive functions and
electrophysiological alterations can be explained by dif-
ferential pharmacokinetics of these two drugs, as cocaine is
rapidly metabolized with an elimination half-life of several
hours, whereas methamphetamine is eliminated more
slowly, with an elimination half-life averaging 12 h (Cook
et al. 1993; Jeffcoat et al. 1989). Moreover, cocaine differs
from methamphetamine in that cocaine inhibits the reup-
take of dopamine, serotonin, and norepinephrine, whereas
methamphetamine mobilizes and releases these monoam-
ines from storage granules, thus producing rapid and large
increases in synaptic concentrations (Simon et al. 2002,
2004). This might be responsible for the discrepancies in
observed qEEG manifestations associated with chronic
methamphetamine and cocaine abuse.
Only a few studies have examined the qEEG conse-
quences of methamphetamine dependence. They report that
methamphetamine dependent patients exhibited a signiﬁ-
cant power increase in the delta and theta bands as
compared to non-drug-using control. The qEEG patterns
associated with acute withdrawal and recent abstinence in
methamphetamine dependence have not yet been sufﬁ-
ciently described. One study reported that abstinent
methamphetamine dependent patients had increased EEG
power in the delta and theta but not in the alpha and beta
bands. In general, qEEG studies of methamphetamine
addiction are in accordance with other neurocognitive
studies suggesting that methamphetamine abuse is associ-
ated with psychomotor slowing and frontal executive
deﬁcits.
P300 Abnormalities in Cocaine, Methamphetamine,
Heroin Addiction, and Alcoholism
The P300 component of the ERP, occurring 300–600 ms
post-stimulus,isthemostwidelyusedERPinpsychiatryand
other clinical applications (Polich et al. 1994; Polich and
Herbst 2000; Pritchard 1981, 1986; Pritchard et al. 2004).
The amplitude of the P300 reﬂects the allocation of atten-
tional resources, while the latency is considered to reﬂect
stimulus evaluation and classiﬁcation time (Katayama and
Polich 1998; Polich and Herbst 2000). The P300 is usually
obtained in an oddball paradigm, wherein two stimuli are
presentedinarandomorder,oneofthemfrequent(standard)
and another one rare (target) (Polich 1990). A modiﬁcation
of the oddball task has been used where a third, also
rare stimulus (distracter), is presented along with standard
and target stimuli. It was reported that these infrequent
distracters elicit a frontocentral P300, so called P3a,
whereas the rare targets elicit a parietal P300, so called
P3b (Katayama and Polich 1996, 1998). The P3a is recorded
at the anterior scalp locations and has been interpreted as
reﬂecting frontal lobe activity (Gaeta et al. 2003; Knight
1984). Though the P300 response in general is thought to
represent ‘‘context updating/closure,’’ in a three-stimuli
oddball task the P3a is interpreted as ‘‘orienting,’’ and the
P3bisviewedasanindexoftheabilitytomaintainsustained
attentiontotarget(Na ¨a ¨ta ¨nen1990).TheanteriorP3aindexes
the contextual salience of the rare stimuli, whereas the pos-
terior P3b is indexing task-relevance of the stimuli (Gaeta
et al. 2003).
A robust ﬁnding in ERP studies on alcoholism is that
alcoholics as well as individuals at high risk to develop
alcoholism have been shown to have a low P300 amplitude
in various task paradigms (Cohen et al. 2002; Hada et al.
2000; Porjesz et al. 2005; Porjesz and Begleiter 1998).
Kouri et al. (1996) examined the P300 component in
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The results showed no P300 amplitude differences between
the patients and healthy non-drug-dependent volunteers
when patients presented for detoxiﬁcation. However, after
the course of detoxiﬁcation, the P300 amplitude was sig-
niﬁcantly smaller in the cocaine- and heroin-dependent
group than in the non-dependent control group. In a study
by Bauer (2001b) the P300 did not differentiate among
patients characterized by histories of either cocaine, or
cocaine and alcohol, or heroin dependence. Across all the
patient groups, the P300 was signiﬁcantly reduced in
amplitude relative to the P300 ERPs recorded from indi-
viduals with no history of alcohol or drug dependence. This
study also demonstrated that continued abstinence from
heroin and from cocaine and alcohol is also associated with
a trend toward normalization of the P300. In a recent study
of Papageorgiou et al. (2004) the P300 component was
evaluated during the anticipatory period of a short memory
task in 20 patients characterized by a past history of heroin
dependence (6 months abstinence), in 18 current heroin
users and in 20 matched healthy subjects. Abstinent heroin
addicts exhibited a signiﬁcant reduction of the P300
amplitude at the central frontal region, relative to the other
two groups.
The results of early work examining the effect of can-
nabis use and THC administration on visual and auditory
ERPs have been inconclusive (Rodin et al. 1970; Roth
et al. 1973). Later studies of Patrick et al. (1995, 1997)
could not ﬁnd P300 latency differences in audio and visual
oddball tasks between THC users without psychiatric
problems and controls. Although THC users displayed
reduced auditory and visual P300 amplitudes in this study,
when age differences between THC users and controls
were removed, all signiﬁcant P300 amplitude differences
were removed as well.
Acute and chronic use of cocaine exerts neuropharma-
cological effects on amplitude and latency of both anterior
and posterior P300 ERP components (Biggins et al. 1997;
Fein et al. 1996; Herning et al. 1994a; Kouri et al. 1996;
Polich 1990). Longer P300 (P3b) latency without abnor-
malities in amplitude was reported in several studies on
cocaine withdrawal (Herning et al. 1994a; Lukas 1993).
Noldy and Carlen (1997) demonstrated effects of cocaine
withdrawal on the latency of the P300 in an auditory
oddball task. In cocaine-dependent patients, P3a amplitude
decrements over frontal areas are persistent even after long
periods of abstinence (Bauer 1997). The latency of the P3a
was delayed and the amplitude was reduced to novel non-
targets in cocaine and alcohol-dependent subjects com-
pared to controls (Biggins et al. 1997; Hada et al. 2000)i n
auditory and visual three-stimuli oddball tasks.
Several studies have investigated ERP changes associ-
ated with methamphetamine abuse and dependence. The
P300 component of the auditory ERP was reported to show
a prolonged latency in the oddball task in methamphet-
amine dependent subjects with a history of psychosis,
compared to normal controls (Iwanami et al. 1994, 1998).
In particular, the patients with methamphetamine depen-
dence showed reduced P3a amplitude in the reading task
and delayed P3b latency with normal P3b amplitude in the
auditory oddball task. This was interpreted as indicating a
prolonged central noradrenergic dysfunction due to earlier
methamphetamine use.
In most ERP studies the P300 did not differentiate
among patients characterized by histories of either cocaine,
or cocaine and alcohol, or heroin dependence. Across all
the patient groups, the P300 was signiﬁcantly reduced in
amplitude relative to P300 ERPs recorded from individuals
with no history of alcohol or drug dependence. The latency
of the frontal and parietal P300 was reported to be delayed,
and the amplitude was reduced to novel non-targets in
cocaine and alcohol-dependent subjects compared to con-
trols in auditory and visual three-stimuli oddball tasks.
Continued abstinence from heroin, cocaine, and alcohol
was shown to be associated with a trend toward P300
normalization. Several studies have investigated ERP
changes associated with methamphetamine abuse and
dependence. In general, chronic psychoactive substance
abuse and drug dependence are associated with delayed
and attenuated cognitive ERP in auditory and visual odd-
ball tasks.
qEEG and ERP Abnormalities in Addiction:
Psychopharmacological Effects or Trait Markers?
Whether qEEG alterations and P300 decrements found in
most of SUD are only a coincident ‘‘marker’’ of vulnera-
bility or make a direct etiologic contribution to risk for
substance dependence is still unknown (Bauer and
Hesselbrok 2001; Carlson et al. 2002; O’Connor et al.
1994; Polich et al. 1994; Porjesz and Begleiter 1998). The
P300 reduction and abnormal qEEG patterns are seen in
mental disorders that often are comorbid with substance
abuse, such as conduct disorder (Bauer and Hesselbrock
1999, 2001), ADHD (Bauer 1997; O’Connor et al. 1994),
and bipolar or major affective disorder (Friedman and
Squires-Wheeler 1994). Reduced P300 amplitude related to
prefrontal brain dysfunction may suggest that a deﬁcit in
inhibitory control is an underlying mechanism shared by
different psychopathologies (Bauer and Hesselbrock 1999;
Clark et al. 1999; Tarter et al. 2003). According to Bauer
(2002), certain ERP and qEEG abnormalities and impaired
functioning on complex cognitive tests in patients formerly
dependent on cocaine might not be proximately caused by
drug use per se but be more related to comorbid alcohol use
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ings converge on the conclusion that there exists an
inherited predisposition for an externalizing psychopa-
thology that includes ADHD, conduct disorder, and
substance abuse. PTSD seems to heighten the risk for
addiction as well. Thus, the reviewed ﬁndings support the
hypothesis that addicted subjects may manifest a P300
amplitude reduction and qEEG abnormalities as a trait
reﬂecting the CNS disinhibition, which may be a predis-
posing factor for addiction liability, resistance to drug habit
extinction, and relapse vulnerability.
Heritability and Neurotransmitter Considerations in
Substance Use Disorders
There has been a consistent drift in addiction research
between the psychosocial, cognitive and behavioral aspects
of addiction and the biological and genetic emphasis. In
much of the present data relating to genetics and animal
models (Blum et al. 2006; Porjesz et al. 2005; Ryabinin
and Weitemier 2006; Samochowiec et al. 2006), studies
suggest that a genetic predisposition for SUD is an
accepted concept. Much of the genetic research addresses
the inﬂuence of alleles thought responsible in coding for
genes that express phenotypic neurotransmitter production
and distribution; mainly involving endorphins, dopamine
and serotonin. These neurotransmitters, dopamine in par-
ticular, are also suspect in other appetitive and mood
disorders and psychopathologies, of particular note,
Reward Deprivation Syndrome (RDS). RDS is described as
a dysfunction in the Brain Reward Cascade and proposes
that abnormal craving behavior is a consequence of defects
in the DRD2 and D1, D3, D4 and D5 dopaminergic
receptor genes (Blum et al. 2006).
Blum and colleagues (1990, 1993, 1996) described this
syndrome and identiﬁed the D2 dopamine receptor gene as
a possible candidate for susceptibility to alcoholism in
severe alcoholics (Blum et al. 1993) and proposed this
gene’s association with dopamine production and distri-
bution may produce a sevenfold increase in the likelihood
of developing alcohol use problems (Uhl et al. 1993). This
DRD2 dopamine receptor gene and polymorphisms within
its genetic coding speciﬁc to addiction remain unclear due
to its involvement in other disorders; including, obesity
(Blum et al. 2006), Tourette’s syndrome (Comings et al.
1991) pathological aggression and violence, PTSD (Com-
ings et al. 1996) and schizoid—avoidant disorder (Chen
et al. 2005). SUD were classiﬁed as a subtype of RDS and
treatment regimens for these disorders have been classiﬁed
as inadequate (Blum et al. 2007) and research continues in
developing possible genetic interventions that may produce
dopamine and other neurotransmitter regulation in
substance-induced rapid dopamine increase in limbic
regions (Blum et al. 2007).
It is clear that heritability plays an important role in
addictive disorders, however, to what extent environment,
perception and synaptic permanency and plasticity inﬂu-
ence the course of genetic adaptation or maladaptive traits
requires further investigation. Suggested neuroanatomical
substrates involved in SUD implicate mesolimbic and
diencephalon regions; including the substantia nigra,
reticular formation, medial forebrain bundle, nucleus ac-
cumbens, septum pediculum, olfactory tubercule and
hippocampus and suggest that any concentration of alcohol
exposure to these regions would make alcohol use virtually
unavoidable (Myers and Privette 1989).
Studies of EEG Biofeedback in Substance Abuse
Treatment
The Peniston Protocol (Alpha-Theta Feedback)
The early studies of Kamiya (e.g., Nowlis and Kamiya
1970) on self-regulation of alpha rhythm elicited sub-
stantial interest in the potential clinical applications of
alpha biofeedback for SUD treatment. There were reported
several uncontrolled case studies and conceptual reviews
on alpha EEG training for alcohol (DeGood and Valle
1978; Denney et al. 1991; Jones and Holmes 1976; Passini
et al. 1977; Tarbox 1983; Watson et al. 1978) and drug
abuse treatment (Brinkman 1978; Goldberg et al. 1976,
1977; Lamontagne et al. 1977; Sim 1976), but the impact
of alpha biofeedback training as a SUD therapy was not
signiﬁcant.
The bulk of the literature to date regarding EEG bio-
feedback of addictive disorders is focused on alpha-theta
biofeedback. The technique involves the simultaneous
measurement of occipital alpha (8–13 Hz) and theta (4–
8 Hz) and feedback by separate auditory tones for each
frequency representing amplitudes greater than pre set
thresholds. The subject is encouraged to relax and to
increase the amount of time the signal is heard, that is to
say, to increase the amount of time that the amplitude of
each deﬁned bandwidth exceeds the threshold. A variety of
equipment and software has been used to acquire, process,
and ﬁlter these signals, and there are differences in tech-
nique inherent with equipment and software.
Alpha-theta feedback training was ﬁrst employed and
described by Elmer Green and colleagues (Green et al.
1974) at the Menninger Clinic. This method was based on
Green’s observations of single lead EEG during meditative
states in practiced meditators, during which increased theta
amplitude was observed following an initial increased
alpha amplitude, then a drop off of alpha amplitude (theta/
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signal was applied to subjects, states of profound relaxation
and reverie were reported to occur. The method was seen
as useful in augmenting psychotherapy and promoting
individual insight. It could be seen as a use of brain wave
signal feedback to enable a subject to maintain a particular
state of consciousness similar to a meditative or hypnotic
relaxed state over a 30- or 40-min feedback session.
Goslinga (1975) gave the ﬁrst description of the use of
alpha-theta feedback in a SUD treatment program. This
integrated program started in 1973 at the Topeka VA, and
included group and individual therapies. Daily 20-min
EEG biofeedback sessions (integrated with EMG biofeed-
back and temperature control biofeedback) were conducted
over 6 weeks, resulting in free, loose associations, height-
ened sensitivity, and increased suggestibility. Patients
discussed their insights and experiences associated with
biofeedback in therapy groups several times a week, aug-
menting expressive psychotherapy. The ﬁrst published
clinical reports of efﬁcacy of alpha-theta training at the
Topeka VA were by Twemlow and Bowen (1976), who
explored the impact of alpha-theta training on psychody-
namic issues in 67 non-psychotic chronic male alcoholics
in an inpatient treatment program. In this non-controlled
study, they found that ‘‘religiousness’’ as a predictor of
‘‘self-actualization’’ may have increased as a result of
imagery experienced in theta states. This was seen as
positive to the program goal of augmenting Alcoholics
Anonymous as a recovery philosophy. The high suggest-
ibility of the method was acknowledged; ‘‘treatments such
as brainwave training, which utilize abstract, ill understood
techniques are potential repositories of magical projection
and fantasy and would logically be more acceptable to
alcoholics who are able to have ‘faith’ (devoutly or mod-
erately religious)’’ (Twemlow and Bowen 1977). In
another uncontrolled study at the Topeka VA, 21 alcoholics
were reported to exhibit within and across session increases
in raw theta amplitudes at occipital areas bilaterally mea-
sured by single lead EEG during the course of alpha-theta
training, becoming more able to achieve deep states as
manifested by EEG (Twemlow et al. 1977). These initial
studies advanced the utility of biofeedback induced theta
states in promoting insight and attitude change in alco-
holics, with the assumptions that biofeedback-induced
theta states are associated with heightened awareness and
suggestibility, and that this heightened awareness and
suggestibility would enhance recovery. Outcome data
regarding abstinence were not reported.
In the ﬁrst reported randomized and controlled study of
alcoholics treated with alpha-theta EEG biofeedback,
Peniston and Kulkosky (1989) described positive outcome
results. Their subjects were inpatients in a VA hospital
treatment program, all males with established chronic
alcoholism and multiple past failed treatments. Following a
temperature biofeedback pre-training phase, Peniston’s
experimental subjects (n = 10) completed 15 30-min ses-
sions of eyes closed occipital alpha-theta biofeedback.
Compared to a traditionally treated alcoholic control group
(n = 10), and nonalcoholic controls (n = 10), alcoholics
receiving brainwave biofeedback showed signiﬁcant
increases in percentages of EEG recorded in the alpha and
theta rhythms, and increased alpha rhythm amplitudes
(single lead measurements at international site O1). The
experimentally treated subjects showed reductions in Beck
Depression Inventory scores compared to the control
groups. Control subjects who received standard treatment
alone showed increased levels of circulating beta-endor-
phin, an index of stress, whereas the EEG biofeedback
group did not. Thirteen-month follow-up data indicated
signiﬁcantly more sustained prevention of relapse in alco-
holics who completed alpha-theta brainwave training as
compared to the control alcoholics, deﬁning successful
relapse prevention as ‘‘not using alcohol for more than six
contiguous days’’ during the follow-up period. In a further
report on the same control and experimental subjects,
Peniston and Kulkosky (1990) described substantial chan-
ges in personality test results in the experimental group as
compared to the controls. The experimental group showed
improvement in psychological adjustment on 13 scales of
the Millon Clinical Multiaxial Inventory compared to the
traditionally treated alcoholics who improved on only two
scales and became worse on one scale. On the 16-PF per-
sonality inventory, the neurofeedback training group
demonstrated improvement on seven scales, compared to
only one scale among the traditional treatment group. This
small n study employed controls and blind outcome eval-
uation, with actual outcome ﬁgures of 80% positive
outcome versus 20% in the traditional treatment control
condition at 4-year follow up.
The protocol described by Peniston at the Fort Lyons
VA cited above is similar to that initially employed by
Twemlow and colleagues at the Topeka VA and Elmer
Green at the Menninger Clinic, with two additions, i.e., (1)
temperature training and (2) script. Peniston introduced
temperature biofeedback training as a preconditioning
relaxation exercise, along with an induction script to be
read at the start of each session. This protocol (described as
follows) has become known as the ‘‘Peniston Protocol’’ and
has become the focus of research in subsequent studies.
Subjects are ﬁrst taught deep relaxation by skin tempera-
ture biofeedback for a minimum of ﬁve sessions that
additionally incorporates autogenic phrases. Peniston also
used the criteria of obtaining a temperature of 94 before
moving on to EEG biofeedback. Participants then are
instructed in EEG biofeedback and in an eyes closed and
relaxed condition, receive auditory signals from an EEG
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A standard induction script employing suggestions to
relax and ‘‘sink down’’ into reverie is read. When alpha
(8–12 Hz) brainwaves exceed a preset threshold, a pleasant
tone is heard, and by learning to voluntarily produce this
tone, the subject becomes progressively relaxed. When
theta brainwaves (4–8 Hz) are produced at a sufﬁciently
high amplitude, a second tone is heard, and the subject
becomes more relaxed and according to Peniston, enters a
hypnagogic state of free reverie and high suggestibility.
(Although theta increase and alpha decrease are thought by
Peniston to be associated with a deeply relaxed state where
hypnagogic reverie is present, this may simply represent
drowsiness) (Niedermeyer 1999). Following the session,
with the subject in a relaxed and suggestible state, a ther-
apy session is conducted between the subject and therapist
where the contents of the imagery experienced is explored
and ‘‘abreactive’’ experiences are explored (Peniston and
Kulkosky 1989, 1990, 1991).
Saxby and Peniston (1995) reported on 14 chronically
alcohol dependent and depressed outpatients using this
same protocol of alpha-theta brainwave biofeedback. Fol-
lowing treatment, subjects showed substantial decreases in
depression and psychopathology as measured by standard
instruments. Twenty-one month follow-up data indicated
sustained abstinence from alcohol conﬁrmed by collateral
report. These male and female outpatients received 20
40-min sessions of feedback.
Bodenhamer-Davis and Calloway (2004) reported a
clinical trial with 16 chemically dependent outpatients,
10 of whom were probationers classiﬁed as high risk
for re-arrest. Subjects completed an average of 31 alpha-
theta biofeedback sessions. Psychometrics demonstrated
improvements in personality and mood. Follow-up at
74–98 months indicated 81.3% of the treatment subjects
were abstinent. Re-arrest rates and probation revocations
for the probation treatment group were lower than those
for a probation comparison group (40% vs. 79%).
Fahrion (1995) gave a preliminary report (n = 119) on a
large randomized study of alpha-theta training for addic-
tion in the Kansas Prison System using group-training
equipment. A report of the completed study (n = 520)
(Fahrion 2002) showed little difference between the two
groups overall at 2-year outcome. But, when results were
analyzed for age, race and drug of choice, neurofeedback
emerged as a more efﬁcacious treatment for younger and
non-white and non-stimulant abusing participants. Inter-
estingly, this protocol was not effective for cocaine
abusers. (Stimulant abusers will be discussed later in this
article under the Scott–Kaiser modiﬁcation of the Peniston
protocol.)
The issue of alpha-theta biofeedback in culturally sen-
sitive groups that have not responded to traditional modes
of addiction treatment (such as confrontational group
therapies) has been considered in an open case series
reported by Kelly (1997). This three year follow-up study
presented the treatment outcomes of 19 Dine’ (Navajo)
clients. Four (21%) participants achieved ‘‘sustained full
remission,’’ 12 (63%) achieved ‘‘sustained partial remis-
sion,’’ and 3 (16%) remained ‘‘dependent.’’ The majority of
participants also showed a signiﬁcant increase in ‘‘level of
functioning’’.
Schneider et al. (1993) used slow cortical potential
biofeedback to treat 10 unmedicated alcoholic patients in
four neurofeedback sessions after hospitalization. Seven
patients participated in a ﬁfth session an average of
4 months later. Six out of these seven patients had not had
a relapse at the follow-up. These results are similar to those
reported for alpha theta training.
Several other studies using the Peniston protocol and its
modiﬁcations reported cases with positive clinical effects
(Burkett et al. 2003, DeBeus et al. 2002; Fahrion et al.
1992; Finkelberg et al. 1996; Skok et al. 1997). These
studies suggest that an applied psychophysiological
approach based on an alpha-theta biofeedback protocol is a
valuable alternative to conventional substance abuse
treatment (Walters 1998). Nevertheless, most of these
results were reported at the society meetings, and only few
of these studies were published in mainstream peer-
reviewed journals other than The Journal of Neurotherapy.
A critical analysis of the Peniston Protocol is discussed
at length in the previous reviews (Trudeau 2000, 2005a, b).
Several controlled studies of the Peniston protocol for
addictions, completed by Lowe (1999), Moore and Trudeau
(1998), and Taub and Rosenfeld (1994), suggest that alpha-
theta training for addictions may be non-speciﬁc in terms
of effect when compared to suggestion, sham or controlled
treatment, or meditational techniques. By contrast, Egner
et al. (2002) showed that alpha-theta training results in an
increase of theta/alpha ratios, as compared to a control
condition. In an in depth critical analysis that examines
inconsistencies reported in the original Peniston papers,
Graap and Freides (1998) raise serious issues about the
reporting of original samples and procedures in these
studies. In their analyses, the results may have been due as
much to the intense therapies accompanying the biofeed-
back as due to the biofeedback itself. The subjects may
have been comorbid for a number of conditions, which
were not clearly reported, particularly PTSD, which may
have been the focus of the treatment. In his reply to these
criticisms, Peniston (1998) acknowledges that it ‘‘remains
unknown whether the temperature training, the visualiza-
tions, the ATBWNT (alpha-theta brain wave
neurotherapy), the therapist, the placebo, or the Hawthorne
effects are responsible for the beneﬁcial results.’’ The
criticism raised above by Graap and Friedes (1998)
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replication studies. Neither Peniston’s studies nor the rep-
lication studies provide sufﬁcient detail regarding the
speciﬁcs of the types of equipment used for alpha-theta
feedback, including ﬁltering methods for the EEG signal or
other technical information, to permit exact reproduction of
the feedback protocols with other equipment. Outcome
criteria also vary in the replication studies, with varying
measures of abstinence and improvement. An exception to
these concerns is the report of Scott et al. (2005), which
will be discussed later in greater detail.
It should be noted that psychostimulant (cocaine,
methamphetamine) addictions may require approaches and
neurofeedback protocols other than alpha/theta training.
Persons who are cocaine-dependent are cortically under-
aroused during protracted abstinence (Roemer et al. 1995).
qEEG changes, such as a decrease in high beta (18–26 Hz)
power are typical for withdrawal from cocaine (Noldy et
al. 1994). Cocaine abusers who are still taking this drug
often show low amounts of delta and excess amounts of
alpha and beta activity (Alper 1999; Prichep et al. 1999),
whereas chronic methamphetamine abusers usually exhibit
excessive delta and theta activity (Newton et al. 2003).
Thus, cocaine and methamphetamine users may warrant a
different EEG biofeedback protocol, at least at the begin-
ning stages of neurofeedback therapy.
The Scott–Kaiser Modiﬁcation of the Peniston Protocol
Scott and Kaiser (1998) describe combining a protocol for
attentional training (beta and/or SMR augmentation with
theta suppression) with the Peniston protocol (alpha-theta
training) in a population of subjects with mixed substance
abuse, rich in stimulant abusers. The beta protocol is
similar to that used in ADHD (Kaiser and Othmer 2000)
and was used until measures of attention normalized, and
then the standard Peniston protocol without temperature
training was applied (Scott et al. 2002). The study group is
substantially different than that reported in either the
Peniston or replication studies. The rationale is based in
part on reports of substantial alteration of qEEG seen in
stimulant abusers associated with early treatment failure
(Prichep et al. 1996, 2002) likely associated with marked
frontal neurotoxicity and alterations in dopamine receptor
mechanisms (Alper 1999). Additionally, preexisting
ADHD is associated with stimulant preference in adult
substance abusers, and is independent of stimulant associ-
ated qEEG changes. These ﬁndings of chronic EEG
abnormality and high incidence of preexisting ADHD in
stimulant abusers suggest they may be less able to engage
in the hypnagogic and auto-suggestive Peniston protocol
(Trudeau et al. 1999). Furthermore, eyes-closed alpha
feedback as a starting protocol may be deleterious in
stimulant abusers because the most common EEG abnor-
mality in crack cocaine addicts is excess frontal alpha
(Prichep et al. 2002).
In their initial report, Scott and Kaiser (1998) described
substantial improvement in measures of attention and also
of personality (similar to those reported by Peniston and
Kulkosky 1990). Their experimental subjects underwent an
average of 13 SMR-beta (12–18 Hz) neurofeedback train-
ing sessions followed by 30 alpha-theta sessions during the
ﬁrst 45 days of treatment. Treatment retention was signif-
icantly better in the EEG biofeedback group and was
associated with the initial SMR-beta training. A subsequent
published paper (Scott et al. 2005) reported on an expan-
ded series of 121 inpatient drug program subjects
randomized to condition, followed up at 1 year. Subjects
were tested and controlled for the presence of attentional
and cognitive deﬁcits, personality states and traits. The
experimental group showed normalization of attentional
variables following the SMR-Beta portion of the neuro-
feedback, while the control group showed no improvement.
Experimental subjects demonstrated signiﬁcant changes
(p\.05) beyond the control subjects on 5 of the 10 scales
of the MMPI-2. Subjects in the experimental group were
also more likely to stay in treatment longer and more likely
to complete treatment as compared to the control group.
Finally, the one-year sustained abstinence levels were
signiﬁcantly higher for the experimental group as com-
pared to the control group.
The approach of beta training in conjunction with alpha-
theta training has been applied successfully in a treatment
program aimed at homeless crack cocaine abusers in
Houston, as reported by Burkett et al. (2003), with
impressive results. Two hundred and seventy (270) male
addicts received 30 sessions of a protocol similar to the
Scott Kaiser modiﬁcation. One-year follow-up evaluations
of 94 treatment completers indicated that 95.7% of subjects
were maintaining a regular residence; 93.6% were
employed/in school or training, and 88.3% had no sub-
sequent arrests. Self-report depression scores dropped by
50% and self-report anxiety scores by 66%. Furthermore,
53.2% reported no alcohol or drug use 12 months after
biofeedback, and 23.4% used drugs or alcohol only one to
three times after their stay. This was a substantial
improvement from the expected 30% or less expected
recovery in this group. The remaining 23.4% reported
using drugs or alcohol more than 20 times over the year.
Urinalysis results corroborated self-reports of drug use.
The treatment program saw substantial changes in length of
stay and completion. After the introduction of the neuro-
feedback to the mission regimen, length of stay tripled,
beginning at 30 days on average and culminating at
100 days after the addition of neurotherapy. In a later study
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completion of neurofeedback training (Burkett et al. 2005).
The follow-up measures of drug screens, length of resi-
dence, and self-reported depression scores showed
signiﬁcant improvement. It should be noted that this study
had limitations, because neurofeedback was positioned
only as an adjunct therapy to all other faith-based treat-
ments for crack cocaine abusing homeless persons enrolled
in this residential shelter mission and was an uncontrolled
study. Yet the improvement in program retention is
impressive and may well be related to the improved
outcome.
Continuing Research
Self-Perception and Experimental Schemata in the
Addicted Brain
Rex Cannon, Joel Lubar, and Deborah Baldwin of the
Brain Research and Neuropsychology Laboratory at Uni-
versity of Tennessee at Knoxville are performing research
with three goals in mind: First, to attempt to reconcile and
integrate data from all disciplines involved in addiction
research in order to develop a novel approach for neuro-
physiological study pertaining to SUD and conceivably
determine and describe EEG source generators that are
instrumental in the processes of self-perception and expe-
riential schemata utilizing a recently developed assessment
instrument. Second, to utilize this information to develop
an integrative treatment model for addictive disorders
based on this research, involving novel group processing
methods and spatial speciﬁc neurophysiological operant
learning (LORETA Neurofeedback) (Cannon et al. 2006,
2007; Congedo 2003; Congedo et al. 2004), and ﬁnally,
third, to utilize both the assessment and neurophysiological
data for development of statistical models for possible
diagnostic and predictive purposes and to provide a means
for a neurophysiological measure of treatment efﬁcacy.
Research indicates that substance abusers have elevated
beta activity in an EEG resting state as compared with
normative groups (Rangaswany et al. 2002) and elevated
alpha activity after administering a mood altering sub-
stance (Cohen et al. 1993; Kaplan et al. 1985). It is
suggested that many of the neurophysiological markers
may provide information about the state of the individual
prior to the development of an addictive disorder and that
these brain functions are under genetic control (Porjesz
et al. 2002, 2005; Tapert 2004). Kaplan et al. (1985)
reported lower frontal alpha and slow-beta coherence in
alcohol-dependent males and females. Michael et al.
(1993) found higher central alpha and slow-beta coherence,
but lower parietal alpha and slow-beta coherence in males
with alcohol dependence; contrarily, other ﬁndings suggest
that morphine, alcohol and marijuana show increased alpha
2 power in the spectral EEG and relate this to the euphoric
state produced by the drug (Lukas 1989, 1995). Winterer
et al. (2003a, b) described higher left-temporal alpha and
slow-beta coherence and higher slow-beta coherence at
right-temporal and frontal electrode pairs in alcohol-
dependent males and females. De Bruin et al. (2004)
showed that moderate-to-heavy alcohol consumption is
associated with differences in synchronization of brain
activity during rest and mental rehearsal. Heavy drinkers
displayed a loss of hemispheric asymmetry of EEG syn-
chronization in the alpha and low-beta band. Moderately
and heavily drinking males additionally showed lower fast-
beta band synchronization. Decision-making processes and
the ability to form a resistance to drugs, i.e., the ability to
say no, involve numerous brain regions; including, the
insular, somatosensory, orbitofrontal, anterior cingulate
and dorsolateral prefrontal cortices, as well as the amyg-
dala, hippocampus and thalamic nuclei (Bechara 2005).
This research considers the integration of the features of
addicted persons as reported in earlier studies, case reports
and theoretical concepts as vital in understanding behav-
ioral manifestations of the suspected neural pathways that
are premised to be involved in the development of SUD.
Some of the fundamental descriptions of addicted indi-
viduals portray them as passive with dependent strivings,
emotionally immature, abounding with fears of responsi-
bility or independent action and ultimately, infantile
inadequate personalities (Coodley 1961), as well as emo-
tionally, socially, and educationally underdeveloped
(Meyerstein 1964), and immature and regressive (Dorsey
1961; Gerard and Kornetsky 1955; Hill 1962). These
individuals are reported to struggle with afﬁrming positive
thoughts of self-esteem, tendencies to undervalue them-
selves and be self deprecating, and exhibit difﬁculty
adjusting to others and these tendencies are veiled by overt
behavioral patterns, including, physical or verbal abuse.
Individuals with SUD present with a vast number of
paradoxical characteristics; including an overwhelming
sense of inadequacy disguised by an apparent over-
whelming sense of conﬁdence. Similarly, an apparent
abundance of anger and aggression utilized as a disguise
for a paralyzing sense of fear, more speciﬁcally, fear of
people, economic insecurity, rejection, and alienation,
which paradoxically are exacerbated by the continued use
of the substance. One of the more profound idiosyncratic
characteristics of this population is the tendency to rumi-
nate and associate past events, perceptions and the
associated emotions with both present and future. The
perception of experience is often clouded by the person-
alization of events (real or imagined) and reinforced with a
deliberate, ambiguous effort to avoid reconciling this
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all current interactions and situations with past events.
Opposite to what often is implied, these features may not
originate from the consequences of substance abuse, but
from earlier periods in development (Vos 1989), and in the
perspective of this research these features and others have
an etiology in speciﬁc neurophysiological regions that are
the direct result of dendritic pruning that occurs in early
development that continues on into adolescence and, unless
intervention or awareness of these schemata are achieved,
they remain problematic into adulthood.
To date, studies identifying such schematic source
generators and their relationship with SUD using qEEG
and standardized low-resolution electromagnetic tomogra-
phy (sLORETA) are scant. This research is designed to
assess the neural activation patterns relative to schemata
regarding the self in recovering addicts and identify pos-
sible generators in the cortex as compared to controls. In
this research, it is hypothesized that there is dendritic
pruning early in developmental phases that contribute to
frequency speciﬁc activity in neuronal populations in the
ventromedial portions of the prefrontal cortex and limbic
regions. Furthermore, it is proposed that these neural
pathways hinder the integration of affect, cognition, reward
and decision-making processes and adversely inﬂuence the
perception of self and self in relation to experience and the
development of adaptive schemata and personality
characteristics.
Integration of Cognitive Neuroscience Approaches in
Assessment of Functional Outcomes of Neurofeedback
and Behavioral Therapy Based Interventions in SUD
Sokhadze et al. (2007a) in their conceptual review pro-
posed an integrated approach to assessment and treatment
utilizing cognitive neuroscience methods (e.g., qEEG,
ERP), conventional psychotherapeutic treatment, and neu-
rofeedback therapy to assess the recovery of cognitive and
emotional functions affected by chronic psychostimulant
drug abuse co-occurring with PTSD. Cognitive neurosci-
ence methodologies used for assessment of the outcome
effects of psychotherapy and neurofeedback interventions
for comorbid disorders have signiﬁcant potential for addi-
tionally identifying neurophysiological and clinical
markers of treatment progress (Sokhadze 2005). These
outcome markers may provide useful information for
planning bio-behavioral interventions in this form of dual
diagnosis.
Stotts and colleagues (2006) at the University of Texas
at Houston, in collaboration with researchers at Rice
University, used motivational interviewing (MI) with
personalized feedback, particularly employing the ERP
markers of deﬁciencies in selective attention task pro-
duced by cocaine abuse in crack addicts. In a
randomized, controlled pilot study these authors (Stotts
et al. 2006; Sokhadze et al. 2004, 2005) evaluated the
feasibility and preliminary efﬁcacy of a brief MI inter-
vention using EEG/ERP graphical feedback for crack
cocaine abusers. Treatment-seeking cocaine abusers
(N = 31) were randomly assigned to a two-session MI
intervention or a general educational drug conseiling
(control) condition. All participants received EEG
assessments based on dense-array ERP tests in a selective
attention task at intake and post-treatment. Results indi-
cated that the MI intervention was feasible and the
subjective impact of the EEG/ERP feedback was positive.
Signiﬁcant group differences in percentage of cocaine
positive urine screens across the study were found,
favoring the MI group; 84.9% for the control group and
62.6% in the MI group.
In a current study at the University of Louisville, Tato
Sokhadze and his colleagues are utilizing dense-array
qEEG/ERP variables and measures of behavioral perfor-
mance on mental tasks (reaction time, accuracy) to explore
the cognitive functions in patients with cocaine abuse/
dependence diagnosis, and the recovery of these functions
during bio-behavioral intervention based on an integrated
neurofeedback approach (NFB, Scott–Kaiser protocol) and
motivational enhancement therapy (MET) in an outpatient
population. The purpose of this research is also to char-
acterize changes in cognitive functioning associated with
the success rate of three arms for cocaine addiction
treatment (MET, NFB, combined MET + NFB). Prior,
during, and subsequent to the above bio-behavioral ther-
apies, individual differences in qEEG and dense-array
ERP are being assessed during cognitive tasks containing
drug-related and generally affective cues, and during
cognitive tasks aimed to test cortical inhibitory capacity,
selective attention, response error processing, and cortical
functional connectivity. Preliminary data from this study
were presented at the 2007 annual meeting of ISNR
(Sokhadze et al. 2007b) and are being prepared for the
publication.
Efﬁcacy of Alpha Theta Training
The Guidelines for Evaluation of Clinical Efﬁcacy of Psy-
chophysiological Interventions (LaVaque et al. 2002),
which have been accepted by AAPB and ISNR, specify ﬁve
types of classiﬁcation for the effectiveness of biofeedback
procedures, ranging from ‘‘Not empirically supported’’ to
‘‘Efﬁcacious and Speciﬁc.’’ The requirements for each
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complete description may be found in LaVaque et al.
(2002).
Criteria for Levels of Evidence of Efﬁcacy
Level 1: Not empirically supported. This classiﬁcation is
assigned to those treatments that have only been described
and supported by anecdotal reports and/or case studies in
non-peer reviewed journals.
Level 2: Possibly efﬁcacious. This classiﬁcation is
considered appropriate for those treatments that have been
investigated in at least one study that had sufﬁcient sta-
tistical power, well-identiﬁed outcome measures, but
lacked randomized assignment to a control condition
internal to the study.
Level 3: Probably efﬁcacious. Treatment approaches
that have been evaluated and shown to produce beneﬁcial
effects in multiple observational studies, clinical studies,
wait list control studies, and within-subject and between-
subject replication studies merit this classiﬁcation.
Level 4: Efﬁcacious. In order to be considered ‘‘efﬁca-
cious,’’ a treatment must meet the following criteria:
(a) In a comparison with a no-treatment control group,
alternative treatment group, or sham (placebo) control
utilizing randomized assignment, the investigational
treatment is shown to be statistically signiﬁcantly
superior to the control condition or the investigational
treatment is equivalent to a treatment of established
efﬁcacy in a study with sufﬁcient power to detect
moderate differences;
(b) The studies have been conducted with a population
treated for a speciﬁc problem, from whom inclusion
criteria are delineated in a reliable, operationally
deﬁned manner;
(c) The study used valid and clearly speciﬁed outcome
measures related to the problem being treated;
(d) The data are subjected to appropriate data analysis;
(e) The diagnostic and treatment variables and proce-
dures are clearly deﬁned in a manner that permits
replication of the study by independent researchers,
and
(f) The superiority or equivalence of the investigational
treatment have been shown in at least two independent
studies’’ (LaVaque et al. 2002, p. 280).
Level 5: Efﬁcacious and Speciﬁc. To meet the criteria
for this classiﬁcation, the treatment needs to be demon-
strated to be statistically superior to a credible sham
therapy, pill, or bona ﬁde treatment in at least two inde-
pendent studies.
Using these criteria and based on the studies reported to
date alpha-theta training can be classiﬁed as Level 3—
probably efﬁcacious—when combined with an inpatient
rehabilitative treatment modality in subjects with long
standing alcohol dependency. This classiﬁcation is based
on the original randomized and controlled study of the
Peniston Protocol (Peniston and Kulkosky 1989, 1990,
1991) and multiple observational and uncontrolled studies
that preceeded (Twemlow and Bowen 1977, Twemlow
et al. 1977) and followed these studies (DeBeus et al.
2002; Burkett et al. 2003; Fahrion et al. 1992; Finkelberg
et al. 1996; Skok et al. 1997; Bodenhamer-Davis and
Calloway 2004; Saxby and Peniston 1995; Fahrion 1995).
Using these criteria and based on reported studies to date
the Scott–Kaiser modiﬁcation of the Peniston Protocol can
also be classiﬁed as probably efﬁcacious (Level 3) when
combined with residential rehabilitation modalities in
stimulant abusers. This rating is based on one controlled
study of 121 subjects in which Peniston’s outcomes of both
psychometric improvement and abstinence improvement
were replicated (Scott et al. 2005) and one observational
study of 71 subjects (Burkett et al. 2003).
Alpha-theta training protocols do not completely meet
the criteria for the Level 4, ‘‘efﬁcacious’’ classiﬁcation.
Although there are sufﬁcient studies that show statistically
signiﬁcant superiority of randomly assigned treatment
groups to no-treatment control groups, and studies have
been conducted with populations treated for a speciﬁc
problem, from whom inclusion criteria are delineated in a
reliable, operationally deﬁned manner, and the studies cited
use valid and clearly speciﬁed outcome measures related to
the problem being treated with data subjected to appro-
priate data analysis, there remains the shortcoming cited by
Graap and Freides (1998) for the initial reports of Peniston
and Kulkosky (1989, 1990, 1991). We recall the qualifying
limitations of LaVaque et al. (2002), who stated that ‘‘the
diagnostic and treatment variables and procedures are not
clearly deﬁned in a manner that permits replication of the
study by independent researchers’’ (p. 280). However, the
Scott et al. (2005) report does appear to clearly delineate
treatment variables and procedures. One other independent
study showing the superiority of modiﬁed alpha-theta
training to control condition would meet the stated criteria
for a Level 4 ‘‘efﬁcaceous’’ classiﬁcation.
To be considered Level 5 (‘‘efﬁcacious and speciﬁc’’)
modiﬁed alpha-theta training would need to be shown to be
superior to sham or bona ﬁde treatment. It has not been
demonstrated that the Peniston type alpha-theta feedback is
more efﬁcacious than sham treatment (Trudeau 2000,
2005a, b;L o w e1999; Moore and Trudeau 1998) or alter-
native treatment that involves meditation (Taub and
Rosenfeld 1994).
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Implications for Individualized (qEEG-Guided)
Neurofeedback
There are several conditions commonly associated with
addictive disorders that have known neurophysiological
aberrations. The co-occurrence of alcohol and other SUD
with other psychiatric disorders has been widely recog-
nized. Co-occurrence of SUD and other psychiatric
diagnosis (e.g., PTSD, antisocial personality disorder,
ADHD, unipolar depression etc.) is highly prevalent
(Drake and Walach 2000; Evans and Sullivan 1995; Grant
et al. 2004; Jacobsen et al. 2001). Persons with co-occur-
ring other mental disorders and SUD have a more
persistent illness course and are more refractive to treat-
ment than those without dual diagnoses (Brown et al. 1995;
O’Brien et al. 2004; Schubiner et al. 2000; Swartz and
Lurigio 1999). Depression occurs in approximately 30% of
chronic alcoholics (Regier et al. 1990). In treatment set-
tings, these depressed patients can present particular
challenges to the clinician, as they may not respond as well
to treatment as other patients, may have greater relapse,
attrition, and readmission rates, and may manifest symp-
toms that are more severe, chronic, and refractory in nature
(Sheehan 1993). Independent of other psychiatric comor-
bidity, ADHD alone signiﬁcantly increases the risk for
SUD (Biederman et al. 1995). Associated social and
behavioral problems may make individuals with comorbid
SUD and ADHD treatment resistant (Wilens et al. 1998).
In males ages 16–23, the presence of childhood ADHD and
conduct disorder is associated with non-alcohol SUD
(Gittleman et al. 1985; Manuzza et al. 1989). In summary
childhood ADHD associated with conduct disorder in
males is an antecedent for adult non-alcohol SUD and anti-
social personality disorder (Wender 1995). The incidence
of ADHD in clinical SUD populations has been studied and
may be as high as 50% for adults (Downey et al. 1997) and
adolescents (Horner and Scheibe 1997). Adult residual
ADHD is especially associated with cocaine abuse and
other stimulant abuse (Levin and Kleber 1995). Monastra
et al. (2005) in a white paper review of ADHD, cite
positive treatment outcomes of just under 80% in treatment
of ADHD with neurofeedback.
Rates of PTSD occurring in persons primarily identiﬁed
with or in treatment for substance abuse vary from 43%
(Breslau et al. 1991) up to 59% (Trifﬂeman et al. 1999). In
a general population study, Cottler et al. (1992) reported
that cocaine abusers were three times more likely to meet
diagnostic criteria for PTSD compared to individuals
without a SUD. Kalechstein et al. (2000) found that
methamphetamine-dependent individuals are at greater risk
to experience particular psychiatric symptoms. There was
reported a signiﬁcant dependence-by-gender effect, with
methamphetamine-dependent females reporting signiﬁ-
cantly more overall posttraumatic stress symptomatology
compared to females reporting no dependence, whereas
males signiﬁcantly differed only with respect to depression.
Peniston and Kulkosky (1991) reported effective treatment
of PTSD using a protocol similar to the one they employed
for alcoholics.
Hughes and John (1999) review the applicability of
qEEG ﬁndings in SUD. They note that in numerous qEEG
studies there is a consensus of increased beta relative
power in alcoholism and increased alpha in cannabis and
crack cocaine users. They conclude that the evidence
provided by studies to date is insufﬁcient to recommend
qEEG as a routine clinical assessment tool in SUD,
although it may be useful in differential diagnosis in dif-
ﬁcult cases. A number of speciﬁc qEEG abnormalities have
been described as speciﬁc to suspected neurotoxicities
associated with chronic stimulant abuse. These studies
(Alper et al. 1990; Noldy et al. 1994; Prichep et al. 1996;
Roemer et al. 1995; Trudeau et al. 1999) based on rea-
sonably uniform abstinence times and employing different
EEG technology and analytical approaches, have produced
remarkably similar ﬁndings of alpha relative amplitude
excess with delta relative amplitude deﬁcit that is striking.
Excess alpha amplitude with slowing of alpha frequency
associated with chronic cannabis abuse has been reported
(Struve et al. 1998). As noted, Scott and Kaiser (1998)
describe combining a protocol for attentional training (beta
reward) with alpha-theta training in a population of sub-
jects whose primary drugs of abuse were stimulants and
who had features of ADHD.
It may make good sense clinically to consider speciﬁc
neurotherapy treatment of these disorders either in place of
or preceding alpha-theta therapy, similar to the Scott–
Kaiser approach. Second, applicable neurotherapy
approaches are attractive alternative therapies for coexis-
ting or underlying conditions in SUD clients who have
high-risk behaviors for medication treatment, such as
overdosing, abuse, or poor compliance. While there are no
published systematic studies of neurotherapy treatment of
co-occurring depression, TBI, ADHD, PTSD, or drug
neurotoxicity on the course and outcome of addictive dis-
orders, several recent reports of neurotherapy for
addictions based on qEEG ﬁndings, which in turn may be
related to comorbidities, have been presented. Basically,
this technique involves the use of qEEG to identify patterns
of EEG that deviate from standardized norms, and indi-
vidualized EEG biofeedback protocols to correct them
(Romano-Micha 2003). DeBeus et al. (2002) are presently
conducting a randomized controlled study of neurotherapy
for SUD that examines the difference between a qEEG-
based treatment, a research-based (Scott–Peniston) treat-
ment, and a wait-list control for chemically dependent
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torically, alpha-theta training has been the accepted
approach in treating chemical dependency, this study
suggests qEEG-based training is a viable alternative,
demonstrating similar outcomes for personality change and
abstinence rates. Future directions include determination of
those likely to beneﬁt from one of the particular treatments
or a combination of the two and analysis of long-term
abstinence rates. Gurnee (2004) has presented data on a
series of 100 sequential participants with SUD who were
treated by qEEG-based neurotherapy, with marked heter-
ogeneity of qEEG subtypes and corresponding symptom
complexes. In this clinically derived scheme, qEEGs that
deviate from normative databases, mainly with excess
alpha amplitude, are associated more often with depression
and ADD. Those with deﬁcient alpha amplitude are asso-
ciated with anxiety, insomnia, and alcohol/drug abuse. Beta
excess amplitude is associated with anxiety, insomnia, and
alcohol/drug abuse. Central abnormalities are interpreted as
mesial frontal dysfunction and are associated with anxiety,
rumination, and obsessive compulsive symptoms. The
therapeutic approach is to base neurotherapy on correcting
identiﬁed qEEG abnormalities, i.e., train beta excess
amplitude down when present, while monitoring
symptoms.
Tentative ﬁndings suggest that qEEG variables may be
used to predict those alcoholics and drug abusers most at
risk for relapse. Winterer et al. (1998) were able to predict
relapse among chronic alcoholics with 83–85% success,
signiﬁcantly outperforming prediction from clinical vari-
ables. Although they found more desynchronized (less
alpha and theta and more beta activity) over frontal areas in
alcoholics in general, those individuals who relapsed dis-
played even more of this activity. Bauer (2001) obtained
EEG data on alcohol, cocaine or opioid dependent patients
after 1–5 months of sobriety. Those who had relapsed by
6 months later were also characterized by increased beta
(19.5–39.8 Hz) activity relative to those maintaining
abstinence. Relative beta power was superior to severity of
the alcoholism, depression level, antisocial personality
disorder, childhood conduct problems, family history, or
age as predictors, and was unaffected by the substance of
abuse. The EEG differences between relapse-prone and
abstinence-prone groups were found to be related to the
interaction of two premorbid factors: childhood conduct
disorder and paternal alcoholism. These ﬁndings receive
further support from Bauer (1993) and from Prichep et al.
(1996) who also found that beta activity was predictive of
treatment failure. They found two clusters among cocaine
addicts: One had more severe damage (alpha) and tended to
remain in treatment. Those with less severe alpha excess
and more beta activity tended to leave treatment. They also
discovered that dropouts could not be determined from the
presence of anxiety or depression or demographic
variables.
Treatment of patients with substance abuse disorder by
neurofeedback may become more complicated when
patients present various psychiatric conditions. When
addiction is comorbid with ADHD it is suggested that SMR
(or beta increase, theta decrease) training should be con-
ducted to address the related ADHD disorder ﬁrst
(Biederman et al. 1997). Applicability of neurofeedback
methods to treat anxiety and affective disorders is reviewed
by Hammond (2006). Peniston and Kulkosky (1990)
describe personality normalization in alcoholics treated
with EEG biofeedback. Alpha-theta feedback has also been
reported as efﬁcacious in alcoholics with depressive
symptoms (Saxby and Peniston 1995). There are only a few
case studies on the efﬁcacy of neurofeedback for treating
generalized anxiety disorder (Vanathy et al. 1998) and
PTSD (Huang-Storms et al. 2006; Graap et al. 1997).
Alpha-theta feedback has been described as efﬁcacious in
post-combat PTSD (Peniston and Kulkosky 1991; Peniston
et al. 1993). However, additional research needs to be
completed to determine the clinical outcome and efﬁcacy
of bio-behavioral treatment based on brain wave self-reg-
ulation in addiction disorders that are comorbid with
various anxiety disorders and PTSD.
Clinical Considerations: Cognitive-Behavioral and
Neurofeedback Treatment in Substance Use Disorders
Because of its chronic nature, long-term treatment for SUD
is usually necessary (Crits-Christoph et al. 1997, 1999).
Effective agonist and antagonist pharmacotherapies as well
as symptomatic treatments exist for opioid dependence, but
neither agonists nor antagonists have been approved as
uniquely effective for treatment of stimulant abuse or
dependence (Grabowski et al. 2004). There is no current
evidence supporting the clinical use of carbamazepine
(Tegretol), antidepressants, dopamine agonists (drugs
commonly used to treat Parkinson’s and Restless Leg
Syndrome), disulﬁram (Antabuse), mazindol (an experi-
mental anorectic), phenytoin (Dilantin), nimodipine
(Nimotop), lithium and other pharmacological agents in the
treatment of cocaine dependence (de Lima et al. 2002;
Venneman et al. 2006). Because no proven effective
pharmacological interventions are available for cocaine
addiction or for methamphetamine addiction, treatment of
stimulant addiction has to rely on existing cognitive-
behavioral therapies (CBT) or CBT combined with other
biobehavioral approaches (Van den Brink and van Ree
2003).
According to Volkow et al. (2004) successful strategies
for behavioral treatment in drug addiction may include (1)
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drug and simultaneously increase values of natural rein-
forcement; (2) approaches aimed to change stereotype
conditioned drug-seeking behaviors; and (3) methods to
train and strengthen frontal inhibitory control. Because
stressful events can result in relapse to drug taking
behavior (Koob and Le Moal 2001), an adjunct treatment
strategy is to interfere with the neurobiological responses
to stress (Goeders 2003; Koob and Le Moal 2001). Treat-
ment of comorbid mental conditions may also require the
concurrent treatment of drug addiction. In some cases,
however, comorbid drug addiction may result from
attempts to alleviate the psychiatric disorder through self-
medication (i.e., co-occurring cocaine use and ADHD and/
or heroin addiction co-occurring with PTSD). In other
cases, severity of a psychiatric disorder symptom may
increase as a result of drug abuse (Volkow et al. 2003,
2004).
In patients with drug abuse arising from an attempt to
self-medicate (Khantzian 1985, 1997), treatment of the
comorbid mental disorder may help prevent abuse. For
instance, treatment of the preexisting condition of ADHD
may prevent cocaine abuse (Biederman et al. 1995,
1997). In some cases though the persistent qEEG
abnormalities associated with chronic SUD may happen
to be independent from ADHD clinical status (Trudeau
et al. 1999). The co-occurrence of ADHD and SUD has
received considerable attention in the recent clinical and
scientiﬁc literature (Davids et al. 2005). These two dis-
orders are often linked to one another. Because the core
symptoms of ADHD may be mimicked by the effects of
psychoactive drugs, it is difﬁcult to diagnose one disor-
der in the presence of the other (Davids et al. 2005).
ADHD has been found to be associated with an earlier
onset of SUD (Horner and Scheibe 1997). It is generally
assumed that untreated ADHD is a risk factor for SUD
development (Biederman et al. 1997, 1998; Manuzza
et al. 1998; Trudeau 2005a, b).
In a case of comorbidity in which the use of drugs
antecedes a mental disease (e.g., substance-induced anxiety
disorder, DSM-IV-TR, APA 2000) or is not driven by self-
medication strategies, the simultaneous treatment of both
psychiatric conditions may be required. In this situation,
treatment could be guided by the two following concepts:
(1) Behavioral interventions to activate and strengthen
circuits involved in inhibitory control, such as bio-behav-
ioral self-regulation training, may increase successful
abstinence from drug taking. (2) Considering the important
role of cognitive and emotional processes involved in the
predisposition for drug abuse, the development of non-
pharmacological interventions (e.g., CBT, stress manage-
ment, neurofeedback) is a feasible strategy.
Directions for Further Research
Speciﬁc patterns of qEEG abnormality associated with
speciﬁc substance use toxicity such as those found in stim-
ulant abuse or alcohol abuse or with comorbidities such as
ADHD (Chabot and Serfontein 1996), PTSD (Huang-
Storms et al. 2006) or TBI (Thatcher et al. 1989) suggest
underlyingbrainpathologiesthatmightbeamenabletoEEG
biofeedback that is tailored to the person. These approaches
would likely be individualized rather than protocol based,
and would be used independently or in conjunction with
classic alpha-theta training. By way of example, these could
include protocols speciﬁc to the qEEG abnormality, such as
frontal delta reward to correct the frontal delta deﬁcit in
cocaineabusethatAlper(1999)hypothesizesmayberelated
to cocaine sensitization and changes in dopamine trans-
mission.Toourknowledgethishasneverbeenstudiedandis
clearly a research (not a clinical) recommendation. The
qEEG patterns and abnormalities depend signiﬁcantly on
whether the subject is still currently using, the chronicity of
use, and the current stage of withdrawal or protracted
abstinence. A neurofeedback protocol selected for an indi-
vidualclient withSUD shouldbedirectly related tothelevel
of current substance use or abstinence, especially in such
classes of drugs as heroin, where the withdrawal syndrome
results in substantial physiological manifestations including
transient qEEG changes.
Even though there are no reported systematic studies of
EEG biofeedback treatment of commonly occurring com-
orbidities of SUD, it makes sense that clinical EEG
biofeedback treatment study protocols consider the pres-
ence of ADHD, TBI, depression, and drug-associated
neurotoxicity. This approach may improve outcome,
especially in conventional treatment resistant participants.
Unfortunately, only a few large-scale studies of neuro-
feedback in addictive disorders have been reported in the
literature. Most, if not all of the recommendations previ-
ously made regarding further research (Trudeau 2000,
2005b) have yet to be implemented. These recommenda-
tions are summarized as follows.
(1) Studies require external, systematic replicability of
brain wave feedback methods and results in diverse
populations that include various control and alterna-
tive treatment conditions wherein the groups are
matched on key dimensions.
(2) Details need to be given regarding the equipment that
was used and the associated technical speciﬁcations
(e.g., details about ampliﬁcation, ﬁltering, spectral
extraction, windowing, and other pertinent informa-
tion) needed by neurofeedback specialists for
replication and comparison.
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wave feedback required for therapeutic advantage
need to be stated, including double-blinded studies
that control for all other possible therapeutic
effects.
(4) Open clinical trials that investigate efﬁcacy of the
types of protocols used for ADHD, PTSD, depression,
and TBI remediation with SUD subjects comorbid for
those conditions need to be reported.
(5) Open clinical trials that assess the efﬁcacy of EEG
biofeedback in addressing the speciﬁc qEEG changes
of chronic alcohol, heroin, cannabis and stimulant
abuse need to be reported.
(6) The physiological and psychological processes of the
therapeutic effects of EEG biofeedback, including
studies of qEEG and ERP changes, need to be
investigated and reported.
(7) Studies need to adhere to clearly deﬁned outcome
measures that have established reliability and validity.
Other important recommendations for future develop-
ment of the ﬁeld are listed below:
(a) The availability of an increased number of channels
for EEG and ERP recording (e.g., higher spatial
sampling rate) makes it possible to better localize the
source of brain activity. More focused research of this
type seems warranted.
(b) There are several speciﬁc functional diagnostic tools
from the cognitive neuroscience arsenal that are very
speciﬁc for testing addictive disorders. Those that
may be especially valuable include cue reactivity tests
using qEEG and ERP measures. Cue reactivity is a
very sensate test of motivational relevance of drug-
related items (Carter and Tiffany 1999) that can be
detected using EEG methods.
(c) In addition to using more traditional neurocognitive
tests (TOVA, IVA+, etc.) that are commonly included
in neurofeedback research (e.g., in particular in
studies on effectiveness of neurotherapy in ADHD
treatment) there may be value in incorporating
standardized tests with EEG/ERP recording to assess
executive functions in addicts. Tests that warrant
mention are the Continuous Performance Test (Go-
NoGo task), Stroop test, Eriksen ﬂanker test, etc.
Some of these tests are sufﬁciently sensitive for
assessing recovery of cortical inhibition function
commonly known to be impaired in patients with
SUD.
(d) Testing emotional reactivity and responsiveness in
addiction is another important domain where qEEG
and ERP methods may help to obtain more
effective evaluation of the affective state of recov-
ering addicts.
In future neurofeedback treatment for SUD attempts
should be made to integrate neurotherapy with other well
known behavioral interventions for drug abuse, such as
cognitive-behavioral therapy (CBT) and motivation
enhancement therapy (MET, Miller and Rollnick 2002). As
a population, drug addicts are very difﬁcult to treat, char-
acterized by a low motivation to change their drug habit
and a reluctance to enter inpatient treatment. CBT and
MET are powerful psychotherapeutic interventions that can
help to bring about rapid commitment to change addictive
behaviors. These behavioral therapies are especially useful
for enhancing compliance with drug-dependent individuals
and facilitating their neurofeedback treatment engagement.
Neurofeedback may be among the most promising bio-
feedback modalities for the treatment of adolescents with
addictive disorders because of the neuroplasticity potential
of the adolescent brain. While there is little work available
on the prevention and treatment of SUD in adolescents
utilizing neurotherapy, there is no reason to suspect that the
approaches used in adults would not be applicable in SUD
adolescents (Trudeau 2005b).
The EEG biofeedback treatment of ADHD may be
important in prevention for children and adolescents at risk
for developing SUD. It may be possible that EEG bio-
feedback therapy of childhood ADHD may result in a
decrease in later life SUD (Wilens et al. 1998). This
remains speculative, as there have been no reported studies
of the effects of neurofeedback treatment on prevention of
SUD to date.
There are several important applications of the neuro-
feedback protocols for enhancement of cognitive
performance in healthy subjects (reviewed in Vernon
2005). This promising new line of neurofeedback-based
cognitive neuroscience research (Barnea et al. 2005; Egner
and Gruzelier 2001, 2003, 2004a, b; Egner et al. 2004;
Vernon et al. 2003) has signiﬁcant potential to elucidate
neurobiological mechanisms explaining how neurofeed-
back training may alter and enhance cognition and
behavioral performance in patients with SUD as well.
Drugs of abuse can impair cognitive, emotional and
motivational processes. More qEEG and cognitive ERP
research is needed to characterize the chronic and residual
effects of drugs on attention, emotion, memory, and overall
behavioral performance. More research is needed also to
relate cognitive functionality measures to clinical outcome
(e.g., relapse rate, drug screens, psychiatric status, etc.).
Such qEEG/ERP studies may facilitate the translation of
clinical neurophysiology research data into routine prac-
tical tools for assessment of functional recovery both in
alcoholism and addiction treatment clinics. We believe that
administration of some of above described qEEG assess-
ments at the pre-treatment baseline might provide useful
predictors of clinical outcome and relapse risk.
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P300) measures into cognitive-behavioral and neurofeed-
back based interventions may have signiﬁcant potential for
identifying whether certain qEEG/ERP measures can be
used as psychophysiological markers of treatment progress
(and/or relapse vulnerability), and also may provide useful
information in planning cognitive-behavioral and neuro-
therapy treatment when substance abuse is comorbid with a
mental disorder.
With the advances made in the last several years, it is
hoped that continued interest will be generated to further
study brainwave biofeedback treatment of addictive dis-
orders. Effectiveness in certain ‘‘hard to treat’’ populations
(conventional treatment resistant alcoholics, crack cocaine
addicts, cognitively impaired substance abusers) is prom-
ising. The prospect of an effective medication free,
neurophysiologic, and self-actualizing treatment for a
substance based, brain impaired, and self-defeating disor-
der such as SUD is attractive.
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